What Estalis 50/250 Treats: Main Uses and Benefits

Estalis 50/250 is a type of Hormone Replacement Therapy (HRT) commonly used to address oestrogen deficiency symptoms in postmenopausal women with an intact uterus. The combined treatment may be applied across symptomatic domains where symptoms related to systemic imbalance interfere with daily functioning, including the management of moderate to severe hot flushes, night sweats, and localized urogenital atrophy. This approach assists with maintaining functional stability and supports general well-being during symptomatic phases.

Symptom Relief and Structural Support

This medication plays a role in managing conditions characterized by periods of heightened symptoms. It is used in situations involving certain distressing symptoms such as systemic vasomotor instability and physical discomfort stemming from tissue atrophy. It is considered relevant for easing challenging symptomatic phases and offers a supportive benefit in the long-term management of postmenopausal bone mineral density loss. This therapy generally supports symptomatic management during difficult episodes.

Quick Fact: Support for Vasomotor Symptoms This treatment may assist with reducing the frequency and intensity of disruptive hot flushes and associated night sweats.

Regulatory References

1. European Summary of Product Characteristics (HPRA)

Eligibility for Estalis 50/250

The official population criteria for Estalis 50/250, a combination hormone replacement therapy (HRT) patch, are strictly defined by regulatory documentation.

Eligibility Status	Population Constraint
Allowed	Postmenopausal women who have an intact uterus (womb).
Not Indicated	Pediatric patients (children and adolescents).
Limited Use	Women older than 65 years, where experience is limited.

Contraindications (Must Not Use)

The medicine is strictly contraindicated and must not be used by individuals with the following documented conditions:

• Malignancy History: Known, past, or suspected breast cancer or other oestrogen-dependent malignant tumors (e.g., endometrial cancer).
• Vascular History: Active or past history of Venous Thromboembolism (DVT or PE) or Arterial Thromboembolic Disease (e.g., stroke or heart attack).
• Organ/Systemic Disease: Acute liver disease or liver function tests that have failed to return to normal; known thrombophilic disorders; or Porphyria.
• Genital Health: Undiagnosed abnormal genital bleeding or untreated endometrial hyperplasia.
• Reproductive Status: Women who are pregnant or breastfeeding.

Conditional Use and Restrictions

Use requires caution and monitoring in the presence of conditions like hypertension, diabetes mellitus, leiomyoma (fibroids), endometriosis, and Systemic Lupus Erythematosus (SLE). Furthermore, the therapy is generally not recommended for the prevention of dementia in women 65 years of age and older.

Interactions with other medicines and products

The official interaction profile of Estalis 50/250 is primarily structured around two types of constraints: metabolic processing interference and formal regulatory restrictions.

---

Metabolic Exposure Modification

Many interactions are driven by the influence of other medicines on the Cytochrome P450 3A4 (CYP3A4) enzyme system, which metabolizes the active hormones, estradiol and norethisterone acetate. Substances classified as strong enzyme inducers (such as the antibiotic rifampicin, the anticonvulsant phenytoin, and the herbal product St. John's wort) are documented to accelerate the clearance of the hormones, resulting in decreased plasma concentrations. Conversely, enzyme inhibitors (including certain anti-infective agents or grapefruit juice) can reduce hormone clearance, leading to increased exposure.

---

Regulatory Restrictions and Pharmacodynamic Effects

Certain combinations are officially restricted in the regulatory labeling. Co-administration is not recommended with specific anti-Hepatitis C regimens, such as those containing Ombitasvir, Paritaprevir, and Ritonavir, due to a reported risk of liver enzyme elevation. Similarly, Tranexamic Acid is restricted for co-use due to a heightened risk of thromboembolic events. Additionally, the progestin component may result in a pharmacodynamic interaction by potentially impairing glucose tolerance, which is relevant when co-administered with antidiabetic medicinal products.

Estalis 50/250 is a transdermal delivery system containing estradiol and norethisterone acetate (NETA).

Estradiol functions as a ligand, binding to and acting as an agonist at both the estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta) within target tissues. Binding of the estradiol-receptor complex to estrogen response elements (EREs) on DNA modulates gene transcription, resulting in the expression or repression of specific proteins.

NETA, a synthetic progestin, is rapidly converted to norethisterone (NET). NET acts as an agonist at the progesterone receptor (PR) in the endometrium and other peripheral tissues. Within the endometrial cells, NET modulates gene transcription, inducing secretory transformation. This intracellular cascade counteracts the proliferative signaling pathway initiated by unopposed estradiol at the ERs in the uterus, mitigating excessive cell division and growth of the endometrial lining. Systemically, both components modify the hypothalamic-pituitary-ovarian axis signaling.

Estalis 50/250 is administered exclusively via the transdermal route, meaning the medication is delivered through a patch system applied directly to the skin. The regimen follows a continuous combined therapy principle, ensuring the uninterrupted, daily release of both estradiol (50 mug) and norethisterone acetate (250 mug).

Official Administration Schedule

Administration requires the application of a new patch twice weekly, resulting in a consistent replacement interval of three or four days to maintain stable hormone levels. The Estalis 50/ 250 strength is generally the standard regimen used for initiation and maintenance. If an application is missed or delayed, a new patch should be applied as soon as possible to continue the established twice-weekly schedule.

Procedural Instructions

For proper administration, the patch must be placed on a clean, dry area of the trunk below the waistline, such as the abdomen or buttocks, and must never be applied to the breasts. It is a procedural requirement that the user rotates the application site with each new patch, ensuring that the same specific area is not used again for at least one week. The transdermal system is to be applied whole immediately after opening its protective pouch.

Research Evidence / Overview of Studies for Estalis 50/250

Evidence for Vasomotor Symptom Assessment

Research for the Estalis 50/250 transdermal patch was studied for its approved use through short-term, randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms, particularly focusing on postmenopausal women who had an intact uterus and were experiencing frequent moderate-to-severe hot flushes and night sweats. Researchers monitored the change in the frequency and intensity of these symptoms as outcomes related to systemic or functional imbalance. Findings describe patterns observed in the studies where the short-term use was monitored for changes in the measured frequency of hot flushes compared to groups that received a placebo.

Evidence for Endometrial Safety and Protection

Intermediate-term clinical trials were central to the evaluation of the progestin component of the combination patch. The treatment was evaluated in studies exploring the continuous inclusion of norethisterone acetate in relation to the lining of the uterus in women who still possess this organ. Studies monitored outcomes such as the incidence of endometrial hyperplasia (an overgrowth of the uterine lining). The studies reported that the inclusion of the progestin component was observed in some studies that measured the incidence of hyperplasia over the observation period. The research so far indicates that the data for the prevention of endometrial hyperplasia is robust for the intermediate-term (up to two years).

Evidence for Postmenopausal Bone Health Maintenance

The use of the patch was studied for the maintenance of bone health in postmenopausal women, especially those at increased risk of bone fracture. Research examined outcomes by focusing on changes in Bone Mineral Density (BMD) at the lumbar spine and hip. Findings describe patterns observed in these studies where the outcomes related to bone density were often maintained or evolved over the follow-up period. Research provides context on the influence the estrogen component may have on markers of bone metabolism.

Evidence Gaps and Follow-up Limitations

Research examined various populations in the clinical development; however, the regulatory summaries often note that there is limited information available for women over 65 years of age within the specific clinical development program. Results apply only to the populations studied, and subgroup findings are uncertain for those with complex medical histories. The most extensive data on fracture incidence was associated with large-scale oral hormone therapy trials, and direct extrapolation to this transdermal formulation may involve uncertainty. Long-term effects for the continued effectiveness and safety are not fully established for the duration of use beyond a few years.

Key Studies & References

1. European Summary of Product Characteristics (SPC) for Estalis 50/250 (Estradiol/Norethisterone Acetate Transdermal Patch)
2. National Institute for Health and Care Excellence (NICE) Guideline: Menopause Diagnosis and Management

Common questions about Estalis 50/250 (FAQ)

Q: Why is it called '50/250'?

The name Estalis 50/250 refers to the approximate daily amounts of the two hormones that the patch is designed to release. Official product information states that the system releases about 50 mug of estradiol and 250 mug of norethisterone acetate over a 24-hour period.

Q: Does Estalis 50/250 come in different dosages?

Official regulatory documents indicate that Estalis is available in more than one strength. Estalis 50/250 represents one specific strength, while a lower strength, typically Estalis 50/140, is also listed in regulatory materials.

Q: How quickly does Estalis 50/250 start working after applying the first patch?

Clinical studies often assess changes in symptoms like hot flushes over several weeks. In these research contexts, reductions in symptom frequency and severity were monitored, with patterns of change typically observed within the first four to eight weeks of consistent use.

Q: How long does the effect of one Estalis 50/250 patch last?

The transdermal system is designed to provide continuous hormone delivery. Official documentation specifies that one patch is intended to cover a three-to-four-day period to maintain stable hormone levels.

Q: What is the main difference between Estalis and an oral pill for the same condition?

The key distinction is the method of administration. Estalis 50/250 is a transdermal patch, which allows hormones to enter the bloodstream directly through the skin. This route bypasses the initial metabolic processing (first-pass metabolism) that occurs in the liver with oral pills.

Q: Is Estalis 50/250 known to cause weight changes?

Official regulatory safety data lists weight changes (which may include either weight gain or loss) as a common side effect. This means it has been observed to affect between 1 in 100 and 1 in 10 users in clinical data.

Q: Can Estalis 50/250 cause mood swings or emotional changes?

Regulatory bodies note that depression is listed as a common side effect in clinical data for this product. Other mood-related effects are generally recognized in the context of hormonal treatments.

Q: What are the skin irritation concerns with the Estalis 50/250 patch?

Reactions at the application site, such as rash, redness, or itching (pruritus), are classified as very common side effects. Regulatory documentation notes that these local skin reactions may be more noticeable when first starting treatment.

Q: What happens if the Estalis 50/250 patch falls off early?

Official patient instructions describe what to do if the system detaches. Generally, the instructions involve attempting to re-apply the original patch or applying a replacement, while maintaining the overall established schedule.

Q: Can the patch be exposed to water during swimming or showering?

Official patient instructions indicate that the transdermal patch is designed to be water-resistant. It is generally expected to remain adhered during activities such as showering, bathing, or swimming.

Q: Are there any dietary restrictions mentioned for people using Estalis 50/250?

The primary specific dietary item mentioned in the official interaction profile is grapefruit juice. Regulatory text warns that it can affect the metabolism of the active ingredients, potentially leading to increased hormone exposure.

Q: Can extreme heat affect how well Estalis 50/250 works?

Official administration procedures indicate that the patch should not be applied to irritated or damaged skin. Additionally, the rate of transdermal absorption could potentially be influenced by high skin temperature, such as from a fever or extended exposure to intense heat.

Q: What should be done if I miss a patch change day?

Official documentation for a missed application indicates that a new patch should be applied quickly, and the established twice-weekly change day should be maintained thereafter.

Q: Does Estalis 50/250 affect blood pressure?

The regulatory label specifies that conditions like pre-existing hypertension (high blood pressure) require caution and monitoring. This monitoring is typically overseen by a healthcare professional.

Q: Is Estalis 50/250 linked to changes in vision?

Official prescribing information lists a sudden, partial, or complete loss of vision (related to vascular issues in the eye) as an adverse event that requires the immediate discontinuation of treatment and medical attention.

Q: Does Estalis 50/250 interact with common antibiotics?

Official documentation identifies specific antibiotics, such as Rifampicin, as capable of significantly decreasing hormone levels. The possibility of interaction with other broad-spectrum antibiotics exists, which requires consideration.

Q: Does Estalis 50/250 contain any latex?

Based on the review of non-medicinal ingredients listed in the official product monograph, components like the silicone and acrylic-based adhesives used in the patch do not contain natural rubber latex.

Q: Can I cut the Estalis 50/250 patch if I feel the dose is too strong?

Official patient instructions specifically advise against cutting the patch. The transdermal system is an engineered product designed to be applied whole immediately after it is opened to ensure proper hormone delivery.

Q: How is Estalis 50/250 meant to be removed without irritation?

Official guidelines advise that after gently peeling off the patch, any adhesive residue that remains on the skin should be gently rubbed with an oil-based cream or lotion. This practice helps minimize potential skin irritation.

Q: What research is available on the maintenance of bone health?

Clinical trials for this patch studied outcomes related to the maintenance of Bone Mineral Density (BMD) in postmenopausal women. The findings describe patterns observed in these studies where the outcomes related to bone density were often maintained or evolved over the follow-up period.

Storage and Disposal of Estalis 50/250 Patches

Estalis transdermal patches must be stored under specific conditions to maintain product stability and must be handled carefully to prevent accidental exposure to children or pets.

Storage Requirements

Condition	Requirement	Constraint
Temperature	Permitted between 2 C and 8 C (refrigerated) or 20 C to 25 C (room temperature).	Must not be frozen.
Packaging	Store in the original sealed pouch and carton.	Use immediately after opening the pouch.
Protection	Keep away from direct light.	If stored at room temperature, use within six months of purchase.

Disposal and Safety

Used and unused patches must be kept out of the sight and reach of children and pets. After removal, the used patch must be folded in half, sticky sides together, and placed in a secure container for disposal. Do not dispose of the medicine via wastewater or flush down the toilet. Unused or expired patches should be discarded according to local regulations, often by returning them to a pharmacy.